Skip to content
Zai Lab
-
Zai Lab accelerates global launch plans for Zoci with landmark European ODD
The EMA Committee for Orphan Medicinal Products supported the designation after recognising a strong unmet need in neuroendocrine carcinomas.
-
Boehringer Ingelheim partners with Zai Lab for dual-targeting lung cancer trial
The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).
-
Zai Lab secures China approval for Augtyro to treat NTRK fusion-positive solid tumors
The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.